BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18337654)

  • 1. Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
    Moncrieff M; Shannon K; Hong A; Hersey P; Thompson J
    Melanoma Res; 2008 Apr; 18(2):161-2. PubMed ID: 18337654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib-induced erythema multiforme.
    MacGregor JL; Silvers DN; Grossman ME; Sherman WH
    J Am Acad Dermatol; 2007 Mar; 56(3):527-8. PubMed ID: 17241689
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sorafenib].
    Hansen A; Eschenhagen T
    Dtsch Med Wochenschr; 2010 Sep; 135(37):1819-22. PubMed ID: 20730706
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib-induced palmoplantar hyperkeratosis.
    Lountzis NI; Maroon MS
    J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
    Lee SH; Paietta E; Racevskis J; Wiernik PH
    Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
    Rey PM; Villavicencio H
    Oncology; 2008; 74(3-4):245-6. PubMed ID: 18716419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
    Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
    Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
    Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
    Hauschild A
    J Dtsch Dermatol Ges; 2007 Apr; 5(4):345. PubMed ID: 17376105
    [No Abstract]   [Full Text] [Related]  

  • 12. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
    Ono S; Tanioka M; Fujisawa A; Tanizaki H; Miyachi Y; Matsumura Y
    Arch Dermatol; 2012 Jun; 148(6):683-5. PubMed ID: 22710450
    [No Abstract]   [Full Text] [Related]  

  • 14. Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
    Raymond AK; Puri PK; Selim MA; Tyler DS; Nelson KC
    Arch Dermatol; 2010 Dec; 146(12):1438-9. PubMed ID: 21173337
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
    Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
    Smith KJ; Haley H; Hamza S; Skelton HG
    Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
    Frieling T; Heise J; Wassilew SW
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):e1-2, 1464-6. PubMed ID: 19572243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quo vadis with targeted drugs in the 21st century?
    Bergh J
    J Clin Oncol; 2009 Jan; 27(1):2-5. PubMed ID: 19047306
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.